← Back

Wire · opportunities

Revenio's iCare DRSplus included in FDA-cleared AI solution for diabetic retinopathy screening

Published

17 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at tradingview.com →

◆ Verified

Fusion42 · 17 August 2026 · Fusion42 review

Revenio's iCare DRSplus fundus imaging system is included in the first FDA-cleared AI-based diabetic retinopathy screening solution in the US, developed by iHealthScreen. The AI software enables automatic identification of patients needing further screening, targeting improved access and early detection in primary care settings.

This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

FDA clearance for AI-enabled diabetic retinopathy screening using iCare DRSplus opens a new route for US primary care providers to integrate automated eye disease detection. You can now move to secure partnerships with primary care clinics aiming to add AI screening and grow your footprint in digital diagnostics.

◆ Coverage

2 sources · 17 Aug 2026

◆ Related on Wire

◆ Topics

Medtechfda-clearancediabetic-retinopathyai-screeningeye-caremedtechus-market